Ci Capital Stock Recommendations and Price Targets

This is a list of recent ratings by Ci Capital.

DateCompany NameActionCurrent
Price
Price
Target
RatingImpact on
Share Price
8/12/2021
FRU
Freehold Royalties
Boost Price TargetC$11.00 C$12.50N/A
9/14/2020
IFRX
InflaRx
Reiterated Rating$5.00 $7.00HoldHigh
9/9/2020
ODT
Odonate Therapeutics
Reiterated Rating$2.00 $50.00BuyMedium
8/18/2020
CALT
Calliditas Therapeutics AB (publ)
Reiterated Rating$18.00 $44.00BuyLow
8/13/2020
BLU
BELLUS Health
Reiterated Rating$6.00 $7.00BuyMedium
8/11/2020
AVDL
Avadel Pharmaceuticals
Reiterated Rating$8.00 $22.00BuyLow
8/6/2020
VYNE
VYNE Therapeutics
Reiterated Rating$1.00 $28.00BuyLow
8/6/2020
CBIO
Catalyst Biosciences
Reiterated Rating$1.00 $18.00BuyLow
8/5/2020
IMVT
Immunovant
Reiterated Rating$8.00 $32.00BuyMedium
8/5/2020
RCKT
Rocket Pharmaceuticals
Reiterated Rating$25.00 $35.00BuyHigh
7/22/2020
CBIO
Catalyst Biosciences
Reiterated Rating$1.00 $19.00BuyLow
7/5/2020
MEIP
MEI Pharma
Reiterated Rating$3.00 $9.00BuyHigh
6/24/2020
LJPC
La Jolla Pharmaceutical
Reiterated Rating$4.00 $8.00BuyHigh
6/22/2020
MEIP
MEI Pharma
Reiterated Rating$3.00 $9.00BuyHigh
5/28/2020
IFRX
InflaRx
Reiterated Rating$5.00 $7.00HoldMedium
3/28/2019
AGF.B
AGF Management
Lower Price TargetC$8.00C$6.50 ➝ C$6.00N/A